EU Approves Roche's Perjeta to Treat Metastatic Breast Cancer
Published: Mar 06, 2013
Roche announced that it has received approval from European regulators for its perjeta drug to help treat breast cancer. The approval comes from the European Medicines Agency and covers patients with previously untreated HER2-positive metastatic breast cancer. The drug is approved in combination with two other treatments - Herceptin and docetaxel - in adult patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. The European approval comes after a late-stage trial showed that the combination of perjeta, Herceptin and chemotherapy provided patients with a median of 6.1 months longer without their disease worsening.